Ras oncogenes are the most frequently identified oncogenes in human cancers. The ras oncogene product, p2lras, is post-translationary modified by the enzyme p2lras farnesyl:protein transferase which transfers farnesyl from farnesyl pyrophosphate, a cholesterol biosynthesis intermediate, to cysteine of the p21ras carboxy terminal CAAX (C=cysteine, A=aliphatic amino acid, X=any amino acid). This farnesylation leads to p2lras- membrane association which is an absolute requirement for p2lras- transforming activity in cultured cells. The overall goal of this proposal is to enhance our understanding of the importance of p2lras - membrane association in ras oncogene neoplasia in vivo and to design strategies to inhibit human tumor growth based on interference with the biochemical steps involved in p2lras membrane association. This will be accomplished by: 1) evaluating the antitumor activity of inhibitors of p2lras membrane association such as lovastatin and other cholesterol biosynthesis inhibitors in nude mice implanted with human tumors expressing various forms of ras oncogene, 2) purifying p2lras farnesyl:protein transferases from human tumors, 3) synthesizing novel analogues of farnesyl pyrophosphate, CAAX tetrapeptide derivatives as well as farnesyl pyrophosphate/CAAX transition state analogues and suicide inhibitors, and 4) determining the ability of these analogues to inhibit p2lras farnesyl:protein transferase, membrane association and human tumor growth in nude mice. The antitumor studies will be carried out in nude mice bearing human tumors expressing various forms of ras oncogenes. The p2lras farnesyl:protein transferases will be purified from human tumor cells by a recently published method using p2lras carboxy terminal CAAX peptide affinity chromatography. The synthetic analogues will first be screened based on their ability to inhibit the purified p2l- farnesyl:protein transferases. The selected inhibitors will then be tested for their ability to inhibit p2lras membrane association, human tumor cell growth in culture and in vivo in nude mice. The membrane association assay will be carried out by immunoprecipitation and western blotting of cytosolic and membrane-associated p2lras. This proposal seeks to broaden the spectrum of human tumors that can be treated chemotherapeutically by evaluating the antitumor activity of inhibitors of p2lras membrane association. The development of p2lras farnesyl:protein transferase assay has great potential as a powerful screening bioassay for the discovery of novel anticancer drugs that inhibit ras oncogene function.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA055823-02
Application #
3200379
Study Section
Experimental Therapeutics Subcommittee 1 (ET)
Project Start
1992-05-01
Project End
1995-04-30
Budget Start
1993-05-01
Budget End
1994-04-30
Support Year
2
Fiscal Year
1993
Total Cost
Indirect Cost
Name
University of Pittsburgh
Department
Type
Schools of Medicine
DUNS #
053785812
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213
McGuire, T F; Sebti, S M (1997) Geranylgeraniol potentiates lovastatin inhibition of oncogenic H-Ras processing and signaling while preventing cytotoxicity. Oncogene 14:305-12
Vogt, A; Qian, Y; McGuire, T F et al. (1996) Protein geranylgeranylation, not farnesylation, is required for the G1 to S phase transition in mouse fibroblasts. Oncogene 13:1991-9
Vogt, A; Sun, J; Qian, Y et al. (1995) Burkitt lymphoma Daudi cells contain two distinct farnesyltransferases with different divalent cation requirements. Biochemistry 34:12398-403
Lerner, E C; Qian, Y; Blaskovich, M A et al. (1995) Ras CAAX peptidomimetic FTI-277 selectively blocks oncogenic Ras signaling by inducing cytoplasmic accumulation of inactive Ras-Raf complexes. J Biol Chem 270:26802-6
McGuire, T F; Qian, Y; Blaskovich, M A et al. (1995) CAAX peptidomimetic FTI-244 decreases platelet-derived growth factor receptor tyrosine phosphorylation levels and inhibits stimulation of phosphatidylinositol 3-kinase but not mitogen-activated protein kinase. Biochem Biophys Res Commun 214:295-303
Lerner, E C; Qian, Y; Hamilton, A D et al. (1995) Disruption of oncogenic K-Ras4B processing and signaling by a potent geranylgeranyltransferase I inhibitor. J Biol Chem 270:26770-3
Sun, J; Qian, Y; Hamilton, A D et al. (1995) Ras CAAX peptidomimetic FTI 276 selectively blocks tumor growth in nude mice of a human lung carcinoma with K-Ras mutation and p53 deletion. Cancer Res 55:4243-7
Kauffmann, R C; Qian, Y; Vogt, A et al. (1995) Activated Drosophila Ras1 is selectively suppressed by isoprenyl transferase inhibitors. Proc Natl Acad Sci U S A 92:10919-23